IC
COGT icon

Ikarian Capital’s Cogent Biosciences COGT Stock Holding History

Ikarian Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-262,600
Closed -$1.89M – 177
2025
Q2 		$1.89M Buy
+262,600
New +$1.46M 0.36% 69

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital's COGT Position: Q4 2025 in Review

Ikarian Capital sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 11,280 shares — an estimated $162K sold.

Ikarian Capital first reported a position in COGT in Q4 2020 and held it in 12 quarters. The position peaked at $7.44M in Q2 2025. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

  • Ikarian Capital reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 11,280 Cogent Biosciences shares in Q4 2025, an estimated $162K.
  • Ikarian Capital first reported a position in Cogent Biosciences in Q4 2020 and held it in 12 quarters.
  • Ikarian Capital's Cogent Biosciences position peaked at $7.44M in Q2 2025.
  • 267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.